1. 3099 Phase 3 trial (NGR015) of best investigator choice (BIC) with or without NGR-hTNF in previously treated malignant pleural mesothelioma (MPM). (September 2015) Authors: Gregorc, V.; Gaafar, R.; Favaretto, A.; Grossi, F.; Jassem, J.; Polychronis, A.; Bidoli, P.; Tiseo, M.; O'Brien, M.; Shah, R.; Taylor, P.; Novello, S.; Muzio, A.; Bearz, A.; Badurak, P.; Greillier, L.; Fontana, F.; Colombi, S.; Lambiase, A.; Bordignon, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S634 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. (September 2015) Authors: Stahel, R.A.; Dafni, U.; Gautschi, O.; Felip, E.; Curioni-Fontecedro, A.; Peters, S.; Massutí, B.; Cardenal, F.; Aix, S.P.; Früh, M.; Pless, M.; Popat, S.; Kotsakis, A.; Cuffe, S.; Bidoli, P.; Favaretto, A.; Carcereny, E.; Sanchez Ronco, M.; Molina, M.A.; Rosell, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S711 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study. (16th January 2014) Authors: Cazzaniga, M. E.; Torri, V.; Villa, F.; Giuntini, N.; Riva, F.; Zeppellini, A.; Cortinovis, D.; Bidoli, P. Other Names: Kahán Zsuzsanna Academic Editor. Journal: International journal of breast cancer Issue: Volume 2014(2014) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer. Issue 4 (July 2016) Authors: Di Bartolomeo, Maria; Pietrantonio, Filippo; Rulli, Eliana; Poli, Davide; Berenato, Rosa; Caporale, Marta; Bajetta, Emilio; Floriani, Irene; Bajetta, E.; Di Bartolomeo, M.; Catena, L.; Schiavo, M.; Pinotti, G.; Proserpio, I.; Rosati, G.; Bordonaro, R.; Cordio, S.; Burrafato, G.; Bochicchio, A.M.;... Journal: Tumori Issue: Volume 102:Issue 4(2016) Page Start: e15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. (May 2021) Authors: Rosati, Gerardo; Lonardi, Sara; Galli, Fabio; Di Bartolomeo, Maria; Ronzoni, Monica; Zampino, Maria G.; Banzi, Maria; Zaniboni, Alberto; Pasini, Felice; Bozzarelli, Silvia; Garattini, Silvio K.; Ferrari, Daris; Montesarchio, Vincenzo; Mambrini, Andrea; Ciuffreda, Libero; Galli, Francesca; Puscedd... Journal: European journal of cancer Issue: Volume 148(2021) Page Start: 190 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗